Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/20/2025

Treatment and Management of Premalignant Breast Lesions

Classification and Risk Assessment

  • Nonproliferative lesions, including benign calcifications and fibrocystic changes, carry minimal increased risk 2

Management Algorithm

  • Surgical excision is recommended for definitive diagnosis and risk reduction in patients with atypical hyperplasia or LCIS, according to the National Comprehensive Cancer Network (NCCN) 1
  • Consider risk-reduction therapy with tamoxifen or other agents according to NCCN Breast Cancer Risk Reduction Guidelines for patients with atypical hyperplasia or LCIS 1
  • Regular breast screening with clinical examination 2-3 times per year starting at age 20 is recommended for high-risk women 3
  • Mammographic screening starting at age 30 or earlier depending on family history is recommended for high-risk women 3

Risk-Reduction Strategies

  • For premenopausal women with confirmed atypical hyperplasia or LCIS, consider tamoxifen (20 mg/day for 5 years) or ovarian function ablation combined with tamoxifen 4
  • For postmenopausal women with confirmed atypical hyperplasia or LCIS, consider aromatase inhibitors (anastrozole 1 mg daily or letrozole 2.5 mg daily for 5 years) 4

Follow-up Recommendations

  • For lesions determined to be benign after excision, mammography every 6-12 months for 1-2 years before returning to routine screening is recommended 1
  • For atypical hyperplasia or LCIS, more intensive surveillance with clinical examination every 3-6 months for 3 years, then every 6-12 months for 3 years, then annually is recommended 4

Important Clinical Considerations

  • Geographic correlation between clinical and imaging findings is essential when evaluating suspicious breast lesions 5
  • Core needle biopsy is preferred over fine needle aspiration for tissue diagnosis, but surgical excision is often needed for definitive diagnosis of atypical lesions 5, 6

Common Pitfalls to Avoid

  • Don't rely solely on imaging to determine if a lesion is benign; concordance between pathology, imaging, and clinical findings is crucial 5
  • Don't use aromatase inhibitors alone in premenopausal patients, as no evidence of efficacy is available 4